Loading...
Targeting mitochondrial structure sensitizes acute myeloid leukemia to Venetoclax treatment
The BCL-2 family plays important roles in acute myeloid leukemia (AML). Venetoclax, a selective BCL-2 inhibitor, has received FDA approval for the treatment of AML. However, drug resistance ensues after prolonged treatment, highlighting the need for a greater understanding of the underlying mechanis...
Na minha lista:
| Udgivet i: | Cancer Discov |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6606342/ https://ncbi.nlm.nih.gov/pubmed/31048321 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-0117 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|